May 9, 2022
Eisai said on May 3 that it has downwardly revised its profit forecasts for FY2021 in the aftermath of a negative Medicare coverage decision made in the US for the Alzheimer’s drug Aduhelm (aducanumab). For the year ended March 2022,...read more